Overview

Location [1]
1q21.2
Protein [2]
B-cell CLL/lymphoma 9 protein
Synonyms [1]
LGS

B-cell CLL/lymphoma 9 (BCL9) is a gene that encodes a protein that has an unknown function. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift insertions are observed in cancers such as breast cancer, ovarian cancer, and skin cancer.

BCL9 is altered in 2.92% of all cancers with high grade ovarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, rectal adenocarcinoma, and cervical squamous cell carcinoma having the greatest prevalence of alterations [3].

BCL9 GENIE Cases - Top Diseases

The most common alterations in BCL9 are BCL9 S1213L (0.42%), BCL9 E482K (0.52%), BCL9 A1190P (0.39%), BCL9 D106N (0.85%), and BCL9 D112E (0.22%) [3].

BCL9 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.